Fund moves
75 tracked managers disclosed the same change for Q3 2025. From a 13F filed Nov 13, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 2, 2024 · Filed Oct 14, 2025
CVS Health's and Chief People Officer paid $622 out of pocket for CVS Health shares. Shares held went up 25% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$622
Shares × reported transaction price
<$25K
+25.0%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 1 month
Confirmed open-market purchases by the same insider in the available history
No
Compared with 1 earlier confirmed purchase
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2023 ($9.28M)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-03. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
56 days after results of Aug 7, 2024, 16 days before results of Oct 18, 2024
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Bought 56 days after CVS's last results announcement; 94% of its insiders' purchases since 2018 were made within 30 days after one
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
A securities lawsuit naming the company as a defendant was filed on Sep 6, 2024 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
2 such cases were open. Tatone v. CVS Health Corporation, docket 1:24-cv-06771, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.7% | +0.4% | +1.3% |
| 30 days | −3.5% | +1.0% | −4.6% |
| 90 days | 0.0% | +4.3% | −4.3% |
| 180 days | −3.2% | +3.1% | −6.3% |
| 365 days | +14.8% | +16.0% | −1.3% |
Past results only. Not a forecast.
Fund moves
75 tracked managers disclosed the same change for Q3 2025. From a 13F filed Nov 13, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
63 tracked managers disclosed the same change for Q3 2025. From a 13F filed Nov 13, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
63 tracked managers disclosed the same change for Q3 2025. From a 13F filed Nov 13, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.